NEW YORK--(BUSINESS WIRE)--Apr 17, 2008 - Pfizer Inc said today
that the Canadian Federal Court has upheld a Pfizer patent covering
amlodipine besylate, the active ingredient in Norvasc. The court
issued an order prohibiting regulatory approval of Pharmascience's
proposed product in Canada until Pfizer's amlodipine besylate
patent - Canadian Patent No. 1,321,393 - expires in August 2010.
Pharmascience may appeal the decision to the Federal Court of
Appeal of Canada.

The company noted that legal challenges to this patent in Canada
by other generic manufacturers are still pending.